Affymetrix (Nasdaq: AFFX) and BioDiscovery, Inc. today announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan® Cytogenetics Suite and OncoScan® FFPE Assay Kit.
"CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit are key parts of our cancer portfolio," says Dr. Andy Last, Executive Vice President and Chief Operating Officer at Affymetrix. "Researchers have been finding CNVs and copy neutral changes in liquid and solid tumor samples. With the use of Nexus Copy Number, an advanced discovery tool for interrogating large data sets, researchers have been able to identify biomarkers that drive disease progression. The new Nexus Copy Number for Affymetrix software offers researchers a version of the Nexus Copy Number software that is easier to access and has been specifically tailored for Affymetrix' assays."
"We are thrilled to extend our relationship with Affymetrix through this unique product," said Dr. Soheil Shams, BioDiscovery's Chief Scientific Officer. "The high quality data from the Affymetrix assays performs extremely well in our software for detecting copy number variants. We have customers around the world that have been leveraging the CytoScan Cytogenetics Suite and OncoScan platforms for copy number analysis from different types of cancer samples, and we're pleased to be able to offer this joint solution to help scientists to gain further insights into cancer biology."
Study shows AI can predict prognosis in triple-negative breast cancer